« Previous Next » Sleep Medicine
Volume 10, Issue 4 , Pages 405-406 , April 2009

Xyrem^® safety: The debate continues

Received 23 January 2009 ,Accepted 2 February 2009.

References

Pardi D, Black J. Gamma-hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs. 2006;20:993–1018
- MEDLINE
- CrossRef
Elian AA. Determination of endogenous gamma-hydroxybutyric acid (GHB) levels in antemortem urine and blood. Forensic Sci Int. 2002;128:120–122
Fieler EL, Coleman DE, Baselt RC. Gamma-hydroxybutyrate concentrations in pre- and postmortem blood and urine. Clin Chem. 1998;44:692
- MEDLINE
Kintz P, Villain M, Cirimele V, Ludes B. GHB in postmortem toxicology. Discrimination between endogenous production from exposure using multiple specimens. Forensic Sci Int. 2004;143:177–181
Elliott SP. Further evidence for the presence of GHB in postmortem biological fluid: implications for the interpretation of findings. J Anal Toxicol. 2004;28:20–26
- MEDLINE
Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. New Eng J Med. 2009;360:225–235
Fuller DE, Hornfeldt CS, Kelloway JS, Stahl PJ, Anderson TF. The Xyrem^® risk management program. Drug Safety. 2004;27:1
Bronstein AC, Spyker DA, Cantilena LR, Green JL, et al. 2007 Annual report of the American association of poison control centers’ national poison data system (NPDS): 25^th annual report. Clin Toxicol 2008;46:10,927–1057.
George C, Feldman N. Effects of sodium oxybate (Xyrem^®) on sleep-disordered breathing. Sleep Med. 2006;7:S73
Seeck-Hirschner M, Baier PC, von Freier A, Aldenhoff J, Göder R. Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports. Sleep Med. 2009;10:154–155
Xyrem^® prescribing information. Palo Alto, CA 94304: Jazz Pharmaceuticals, Inc.; 2005.